Repare Therapeutics Inc. agrees to be acquired by XenoTherapeutics, Inc.
Each Repare shareholder estimated to receive US$1.82 per share plus one contingent value right per common share
Transaction expected to close in the first quarter of 2026
Cash Payment
Each shareholder to receive US$1.82 per Common Share at Closing
Contingent Value Right
Shareholders to receive additional cash payments based on specific scenarios
Portfolio Monetization
Repare continues efforts to license or dispose of product candidates and intellectual property
- The Transaction provides cash payment to shareholders and ongoing participation in milestones and royalties from partnerships
- Repare's Board of Directors unanimously determined the Transaction as beneficial for shareholders
- Cash received from prior transactions may increase the payment to Repare shareholders at Closing
The acquisition by XenoTherapeutics, Inc. marks a strategic move for Repare Therapeutics Inc., offering shareholders immediate cash benefits and future opportunities from existing and potential partnerships.